Re: Resverlogix Provides Update on BETonMACE Phase 3 Trial
in response to
by
posted on
Sep 16, 2019 10:03AM
We can come to an educated guess on RRR.
First off, I am glad that they have confirmed 27 months median dosage. That ties in very well with my original estimate of 5000 patient years. If we assume 2200 patients at 27 months median dosage, we get 4950 patient years.
Next, if we assume 7 as MACE rate for placebo, we get implied MACE events as 173. So MACE from dosed patients is 102. RRR implied is 26%.
If we assume 8 as MACE rate for placebo, we get implied MACE events as 198 and implied RRR is 44%.
Any thoughts?